Success Metrics

Clinical Success Rate

66.7%

Based on 4 completed trials

Completion Rate

67%(4/6)

Active Trials

0(0%)

Results Posted

150%(6 trials)

Terminated

2(33%)

Phase Distribution

Ph phase_3

33%

Ph phase_2

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 2Efficacy & side effects

4(66.7%)

Phase 3Large-scale testing

2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(2)

Detailed Status

Completed4

Terminated2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 3

Trials by Phase

Phase 24 (66.7%)

Phase 32 (33.3%)

Trials by Status

completed467%

terminated233%

Recent Activity

0 active trials

Showing 5 of 6

completedphase_2

Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease

NCT04026165

completedphase_2

Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)

NCT02781584

completedphase_2

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

NCT03449446

terminatedphase_3

Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

NCT03053050

terminatedphase_3

Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

NCT03053063

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT04026165Phase 2

Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease

Completed

NCT02781584Phase 2

Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)

Completed

NCT03449446Phase 2

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

Completed

NCT03053050Phase 3

Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

Terminated

NCT03053063Phase 3

Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

Terminated

NCT02466516Phase 2

Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3

Completed

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6